Jinyu Bio-Technology Co Ltd (600201) - Total Liabilities
Based on the latest financial reports, Jinyu Bio-Technology Co Ltd (600201) has total liabilities worth CN¥972.88 Million CNY (≈ $142.36 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Jinyu Bio-Technology Co Ltd (600201) equity growth momentum to track the company's year-over-year net asset growth rate.
Jinyu Bio-Technology Co Ltd - Total Liabilities Trend (1995–2025)
This chart illustrates how Jinyu Bio-Technology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Jinyu Bio-Technology Co Ltd (600201) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Jinyu Bio-Technology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jinyu Bio-Technology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Driven Brands Holdings Inc
NASDAQ:DRVN
|
USA | $3.36 Billion |
|
Banco do Nordeste do Brasil S.A
SA:BNBR3
|
Brazil | R$55.66 Billion |
|
Autohome Inc ADR
F:8AHB
|
Germany | €4.01 Billion |
|
Saigon Beer Alcohol Beverage Corp
VN:SAB
|
Vietnam | ₫10.32 Trillion |
|
Blackbaud Inc
NASDAQ:BLKB
|
USA | $2.31 Billion |
|
NFI Group Inc
TO:NFI
|
Canada | CA$2.61 Billion |
|
Olin Corporation
NYSE:OLN
|
USA | $5.40 Billion |
Liability Composition Analysis (1995–2025)
This chart breaks down Jinyu Bio-Technology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Jinyu Bio-Technology Co Ltd market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jinyu Bio-Technology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jinyu Bio-Technology Co Ltd (1995–2025)
The table below shows the annual total liabilities of Jinyu Bio-Technology Co Ltd from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.06 Billion ≈ $155.22 Million |
-21.39% |
| 2024-12-31 | CN¥1.35 Billion ≈ $197.44 Million |
+10.81% |
| 2023-12-31 | CN¥1.22 Billion ≈ $178.18 Million |
+17.12% |
| 2022-12-31 | CN¥1.04 Billion ≈ $152.14 Million |
-0.38% |
| 2021-12-31 | CN¥1.04 Billion ≈ $152.73 Million |
+2.79% |
| 2020-12-31 | CN¥1.02 Billion ≈ $148.58 Million |
+41.65% |
| 2019-12-31 | CN¥716.78 Million ≈ $104.89 Million |
-34.28% |
| 2018-12-31 | CN¥1.09 Billion ≈ $159.60 Million |
-9.54% |
| 2017-12-31 | CN¥1.21 Billion ≈ $176.42 Million |
+102.61% |
| 2016-12-31 | CN¥595.04 Million ≈ $87.07 Million |
+23.55% |
| 2015-12-31 | CN¥481.62 Million ≈ $70.48 Million |
+3.02% |
| 2014-12-31 | CN¥467.50 Million ≈ $68.41 Million |
+8.76% |
| 2013-12-31 | CN¥429.83 Million ≈ $62.90 Million |
-46.62% |
| 2012-12-31 | CN¥805.23 Million ≈ $117.83 Million |
+9.68% |
| 2011-12-31 | CN¥734.19 Million ≈ $107.44 Million |
-1.40% |
| 2010-12-31 | CN¥744.64 Million ≈ $108.96 Million |
+14.89% |
| 2009-12-31 | CN¥648.15 Million ≈ $94.84 Million |
+24.87% |
| 2008-12-31 | CN¥519.05 Million ≈ $75.95 Million |
-11.53% |
| 2007-12-31 | CN¥586.66 Million ≈ $85.85 Million |
+75.50% |
| 2006-12-31 | CN¥334.28 Million ≈ $48.92 Million |
-28.42% |
| 2005-12-31 | CN¥467.02 Million ≈ $68.34 Million |
+4.96% |
| 2004-12-31 | CN¥444.93 Million ≈ $65.11 Million |
+15.72% |
| 2003-12-31 | CN¥384.49 Million ≈ $56.26 Million |
+35.67% |
| 2002-12-31 | CN¥283.40 Million ≈ $41.47 Million |
+15.89% |
| 2001-12-31 | CN¥244.53 Million ≈ $35.78 Million |
+8.06% |
| 2000-12-31 | CN¥226.29 Million ≈ $33.11 Million |
+59.19% |
| 1999-12-31 | CN¥142.15 Million ≈ $20.80 Million |
+34.03% |
| 1998-12-31 | CN¥106.06 Million ≈ $15.52 Million |
-12.11% |
| 1997-12-31 | CN¥120.67 Million ≈ $17.66 Million |
-7.31% |
| 1996-12-31 | CN¥130.19 Million ≈ $19.05 Million |
-3.02% |
| 1995-12-31 | CN¥134.24 Million ≈ $19.64 Million |
-- |
About Jinyu Bio-Technology Co Ltd
Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined … Read more